CLINICAL USE

Anti-muscarinic:Parkinsonism Drug induced extrapyramidal symptoms

DOSE IN NORMAL RENAL FUNCTION

150–400 mg daily in divided doses

PHARMACOKINETICS

  • Molecular weight                           :305.8
  • %Protein binding                           :95
  • %Excreted unchanged in urine     : 8
  • Volume of distribution (L/kg)       :No data
  • half-life – normal/ESRD (hrs)      :14/–

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Dose as in normal renal function
  • 10 to 20     : Dose as in normal renal function
  • <10           : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Unlikely dialysability. Dose as in normal renal function
  • HD                     :Unlikely dialysability. Dose as in normal renal function
  • HDF/high flux   :Unlikely dialysability. Dose as in normal renal function
  • CAV/VVHD      :Unlikely dialysability. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs

  • None known

    ADMINISTRATION

    Reconstition

    –

    Route

    Oral

    Rate of Administration

    –

    Comments

    –

    • Tags:

    Related News

    ffddfd

    Hyperlipidemia